Compare ATGL & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ATGL | NGEN |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 175.3M |
| IPO Year | 2023 | 2018 |
| Metric | ATGL | NGEN |
|---|---|---|
| Price | $8.90 | $1.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.1K | ★ 542.8K |
| Earning Date | 01-27-2027 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.97 | $1.28 |
| 52 Week High | $50.00 | $5.97 |
| Indicator | ATGL | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 67.36 |
| Support Level | $7.24 | $1.85 |
| Resistance Level | $11.20 | $2.32 |
| Average True Range (ATR) | 0.83 | 0.14 |
| MACD | -0.21 | 0.07 |
| Stochastic Oscillator | 29.46 | 71.88 |
Alpha Technology Group Ltd is a Hong Kong-based AI company. Its business focuses on two main directions: building Exclusive Large Language Model solutions and developing AI Agents. The group specializes in creating Exclusive Large Language Models (LLMs) and bespoke AI platforms. These solutions serve as custom AI brains, enabling enterprises to harness their data for strategic decision-making and operational performance. It guides companies of all sizes through digital transformation with scalable, AI-driven solutions that are ESG-sustainable and designed for long-term growth. The cutting-edge offerings, AlphaClaw AI Agents and the AlphaClaw AI Agent Marketplace to empower organizations across diverse industries to optimize operations, automate workflows, and unlock data-driven insights.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.